Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 103

Results For "NITI"

3231 News Found

Zydus Lifesciences completes 25 years of listing on NSE
News | May 03, 2025

Zydus Lifesciences completes 25 years of listing on NSE

Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores


Thyrocare launches diagnostic lab in Bhagalpur
Healthcare | May 03, 2025

Thyrocare launches diagnostic lab in Bhagalpur

30th Lab in Thyrocare’s expanding network to bring advanced, affordable diagnostics in Bihar and beyond


Dr. Morepen launches Rs. 499 annual multivitamin pack on Labour’s Day
Healthcare | May 01, 2025

Dr. Morepen launches Rs. 499 annual multivitamin pack on Labour’s Day

Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All


Briefs: Alembic Pharmaceuticals  and Bafna Pharmaceuticals
News | May 01, 2025

Briefs: Alembic Pharmaceuticals and Bafna Pharmaceuticals

Alembic Pharmaceuticals commissions new facility at Pithampur


Medanta to set up a 400-bed super specialty hospital in Guwahati
Healthcare | April 30, 2025

Medanta to set up a 400-bed super specialty hospital in Guwahati

The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital


ekincare raises investment from MSD IDEA Studio Asia Pacific
News | April 30, 2025

ekincare raises investment from MSD IDEA Studio Asia Pacific

ekincare has raised a total funding of $22M since 2015 till date


Merck breaks ground on new $1 billion Biologics Center of Excellence in Delaware, US
News | April 29, 2025

Merck breaks ground on new $1 billion Biologics Center of Excellence in Delaware, US

Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA


Merck to acquire US Biopharma firm SpringWorks Therapeutics for enterprise value of $3.4 billion
Biopharma | April 28, 2025

Merck to acquire US Biopharma firm SpringWorks Therapeutics for enterprise value of $3.4 billion

Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide